References
- Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 85–102
- Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ. 1995; 310: 221–4
- Committee on Safety of Medicines. Fluvoxamine (Faverin): adevrse reaction profile. Current Problems 1998; 22
- Trabert W, Hohagen F, Winkelmann G, Berger M. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry. 1995; 28: 95–7
- Kim KY, Craig JM, Hawley JM. Seizure possibly associated with fluvoxamine. Ann Pharmacother. 2000; 34: 1276–8
- Hahn I, Blanacflor G, Hoffman RS, Howland MA. Fluvoxamine overdose producing status epilepticus. Clin Tox 2000; 38: 573
- Deshpande K. Isolated fluvoxamine poisoning presenting with hypertonia and seizures: a case report. Crit Care Resusc. 2002; 4: 177–80
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. Mar 17, 2005; 352(11)1112–20
- Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984; 230: 94–102
- Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. Dec, 1998; 51(3)215–35
- Buchberger R, Wagner W. Fluvoxamine: Safety profile in extensive post-marketing surveillance. Pharmacopsychiatry. 2002; 35: 101–8
- Harmant J, van Rijckevorsel-Harmant K, de Barsy T, Hendrickx B. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet. 1990; 336: 386
- Garnier R, Azoyan P, Chataigner D, Taboulet P, Dellattre D, Efthymiou ML. Acute fluvoxamine poisoning. J Int Med Res. 1993; 21: 197–208